Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:14 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Efficacy Study of Acetazolamide Versus Diazepam in Continuous Spike and Wave/Landau-Kleffner Syndrome
NCT02904265 · Mayo Clinic · PHASE2/PHASE3 · terminated · last registry update 2020-06-11 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Lack of enrollment” | – | Registry record, Mayo Clinic |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against GABRA1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-04-13Also stopped (withdrawn): Synchroneuron Inc., SNC-102 sustained release tablet (NCT02217007)
- 2021-04-13Also stopped (withdrawn): Synchroneuron Inc., SNC-102 + Placebo (NCT02064010)
- 2020-08-17Results posted on the registry: VA Salt Lake City Health Care System, Chlordiazepoxide + Gabapentin (NCT01573052)
- 2020-01-18Results posted on the registry: Eisai Inc., Lemborexant 5 mg + Lemborexant 10 mg (NCT02350309)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision